Arch Therapeutics Presents AC5® Advanced Wound System During Innovation Spotlight at 2021 Symposium on Advanced Wound Care (SAWC)
Arch Therapeutics (OTCQB: ARTH) presented at the Symposium on Advanced Wound Care on October 31, 2021, showcasing the AC5® Advanced Wound System. This innovative technology aids in managing chronic and biofilm-infected wounds, enhancing healing outcomes. Key opinion leaders affirm its unique self-assembling properties that promote optimal debridement and wound treatment. Arch's regulatory approvals for its products bolster its market position in the wound care sector. The company continues to explore new commercial opportunities and clinical data contributions.
- Regulatory authorization received for AC5® Advanced Wound System and AC5 Topical Hemostat in the U.S. and Europe.
- Presentation by key opinion leaders highlights the clinical advantages of AC5® technology in managing chronic wounds.
- None.
Highlights Broad Clinical Benefits of AC5® Technology and Use in Managing Biofilm Infected Wounds
FRAMINGHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, presented at the Symposium on Advanced Wound Care (SAWC) during the “Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care” session on October 31, 2021.
The presentation, led by Terrence W. Norchi, MD, Founder and CEO of Arch and key opinion leader, Randall Wolcott, MD, Founder of the Southwest Regional Wound Care Center, focused on the use of AC5® Advanced Wound System in chronic and non-healing wounds. Key points of note included the clinical advantages of the AC5® technology platform and the potential for AC5® Advanced Wound System to support optimal debridement and manage the challenges associated with biofilm infected wounds.
Dr. Wolcott stated, “AC5® Advanced Wound System contains a unique self-assembling technology that offers a different mode of action. It builds a barrier and a scaffold on host tissue, complements other therapies, and in my experience, can improve wound healing outcomes. Chronic wounds are chronic infections, and biofilm plays a significant role in perpetuating that cycle and interfering with wound healing. I have used AC5® to enable more aggressive debridement to remove biofilm and prevent its subsequent formation.”
Daniel C. Wadsworth, VP of Dermal Sciences of Arch, said, “We are honored to have world-renowned key opinion leaders like Dr. Wolcott discussing clinical use and contributing to our growing body of data on the effectiveness of AC5® Advanced Wound System.”
The Symposium on Advanced Wound Care (SAWC) is the largest gathering of multidisciplinary wound care clinicians in the United States. Continuing education credits are offered for physicians, nurses, pharmacists, podiatrists, physical therapists, and dieticians. More information on the event is available at https://www.sawcfall.com/.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma, and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our ability to recruit additional field sales representatives and their effectiveness, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to obtain the inclusion of our AC5® Advanced Wound System on targeted federal supply schedules, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
or
Michael Abrams
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2333
Email: mabrams@archtherapeutics.com
____________________________________
1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.
FAQ
What is the focus of Arch Therapeutics' recent presentation at the SAWC?
What are the key advantages of the AC5® technology showcased by Arch Therapeutics?
When did Arch Therapeutics present at the Symposium on Advanced Wound Care?
What is the stock symbol for Arch Therapeutics?
